BACKGROUND:Wound infection and dehiscence are both major contributors to postoperative morbidity. One potential cause or co-factor is the use of suture material. A recently introduced subcutaneous suture is coated with triclosan (TC), an antiseptic drug. It is suggested to reduce wound complications. METHODS: To investigate the effect of TC on wound healing a double blind prospective pilot study in women undergoing a breast reduction was performed. Each patient was her own control. After randomisation the TC-coated sutures were used either on the left or right side. The contralateral side was used as the control. The incidence of dehiscence was studied. RESULTS:Twenty-six patients were included. In the TC breasts there was a wound dehiscence in 16 cases, whereas in the control breasts in seven cases a dehiscence was observed (P=0.023). CONCLUSION: These results suggest that TC-coated sutures should be used with caution. These sutures have already been introduced on to the market without good clinical studies and might have potential adverse effects as shown by these data.
RCT Entities:
BACKGROUND: Wound infection and dehiscence are both major contributors to postoperative morbidity. One potential cause or co-factor is the use of suture material. A recently introduced subcutaneous suture is coated with triclosan (TC), an antiseptic drug. It is suggested to reduce wound complications. METHODS: To investigate the effect of TC on wound healing a double blind prospective pilot study in women undergoing a breast reduction was performed. Each patient was her own control. After randomisation the TC-coated sutures were used either on the left or right side. The contralateral side was used as the control. The incidence of dehiscence was studied. RESULTS: Twenty-six patients were included. In the TC breasts there was a wound dehiscence in 16 cases, whereas in the control breasts in seven cases a dehiscence was observed (P=0.023). CONCLUSION: These results suggest that TC-coated sutures should be used with caution. These sutures have already been introduced on to the market without good clinical studies and might have potential adverse effects as shown by these data.
Authors: Johanna Turtiainen; Eija I T Saimanen; Kimmo T Mäkinen; Antti I Nykänen; Maarit A Venermo; Ilkka T Uurto; Tapio Hakala Journal: World J Surg Date: 2012-10 Impact factor: 3.352
Authors: Deverick J Anderson; Kelly Podgorny; Sandra I Berríos-Torres; Dale W Bratzler; E Patchen Dellinger; Linda Greene; Ann-Christine Nyquist; Lisa Saiman; Deborah S Yokoe; Lisa L Maragakis; Keith S Kaye Journal: Infect Control Hosp Epidemiol Date: 2014-06 Impact factor: 3.254
Authors: David Leaper; Andrew J McBain; Axel Kramer; Ojan Assadian; Jose Luis Alfonso Sanchez; Jukka Lumio; Martin Kiernan Journal: Ann R Coll Surg Engl Date: 2010-09 Impact factor: 1.891
Authors: David Leaper; Ojan Assadian; Nils-Olaf Hubner; Andrew McBain; Thomas Barbolt; Stephen Rothenburger; Peter Wilson Journal: Int Wound J Date: 2011-08-19 Impact factor: 3.315
Authors: X Wu; N Z Kubilay; J Ren; B Allegranzi; P Bischoff; B Zayed; D Pittet; J Li Journal: Eur J Clin Microbiol Infect Dis Date: 2016-09-02 Impact factor: 3.267
Authors: Enora Laas; Cécile Poilroux; Corinne Bézu; Charles Coutant; Serge Uzan; Roman Rouzier; Elisabeth Chéreau Journal: Int J Breast Cancer Date: 2012-12-19